Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment
Pieper, Natalia, Zaremba, Anne, Leonardelli, Sonia, Harbers, Franziska Noelle, Schwamborn, Marion, Lübcke, Silke, Schrörs, Barbara, Baingo, Jolanthe, Schramm, Alexander, Haferkamp, Sebastian, Seifert, Ulrike, Sucker, Antje, Lennerz, Volker, Wölfel, Thomas, Schadendorf, Dirk, Schilling, Bastian, Paschen, Annette and Zhao, Fang (2018) Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment. OncoImmunology, e1450127.Date of publication of this fulltext: 28 Jul 2021 17:26
Article
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | OncoImmunology | ||||
| Publisher: | TAYLOR & FRANCIS INC | ||||
|---|---|---|---|---|---|
| Place of Publication: | PHILADELPHIA | ||||
| Page Range: | e1450127 | ||||
| Date | 2018 | ||||
| Institutions | Medicine > Lehrstuhl für Dermatologie und Venerologie | ||||
| Identification Number |
| ||||
| Keywords | METASTATIC MELANOMA; ANTITUMOR-ACTIVITY; VEMURAFENIB; RECOGNITION; IMMUNOTHERAPY; SURVIVAL; INFILTRATION; NEOANTIGENS; DABRAFENIB; TRAMETINIB; BRAF; CD8(+) T cells; MEK; antigens; inhibitor; melanoma; resistance | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 47637 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric